Systemic absorption of dornase alfa after aerosol inhalation in humans is low.
Normally, primobolan depot for salepresent in human serum. Inhalation dornase alpha at doses up to 40 mg for up to 6 days did not lead to a significant increase in the concentration of in the blood serum compared to normal endogenous levels. Serum concentration did not exceed . Following the appointment of dornase alfa twice a day for 24 weeks, mean serum concentrations of DNase did not differ from the average pre-treatment (3.5 ± 0.1 ng / ml), indicating a low systemic absorption or small accumulation.
In CF patients the average concentration of dornase alfa in sputum 15 minutes after inhalation is approximately 3 ug / ml. After inhalation, the concentration of dornase alfa in serum decreases rapidly.
Symptomatic therapy in combination with standard therapy of cystic fibrosis patients with the index of at least 40% of the norm.
Pulmozyme can be used to primobolan depot for sale treat patients with certain chronic lung diseases (bronchiectasis, chronic obstructive pulmonary disease, congenital lung development in children, chronic pneumonia, immunodeficiency condition occurring with lesions of the lungs, and others.), if the physician evaluating mucolytic effect of dornase alfa provides benefits for patients.
Hypersensitivity to the active ingredient of the drug or its components.
Children up to 5 years.
Pregnancy and lactation
Safety Pulmozim not been established for pregnant women. Studies of dornase alfa has not showed impaired fertility, teratogenicity, or the influence of the drug on the development of the fetus in animals.Pulmozyme should be used during pregnancy with caution and only if the benefit to the mother outweighs the potential risk to the fetus. The period of breastfeeding if primobolan depot for saleinto breast milk in women – is unknown. Assign nursing mothers with caution. In lactating monkeys in cynomolgus, receiving high doses of dornase alfa in / were found low concentrations of dornase alfa in breast milk (<0.1% of the serum concentrations). Given the minimal systemic absorption of dornase alfa, do not expect measurable concentrations of dornase alfa in breast milk in women.
Dosing and Administration
The solution in the vials is intended only for a single inhalation use.
Pulmozyme should not be diluted or mixed with other drugs or solutions in the nebulizer container. Mixing of the drug with other drugs can lead to undesirable structural and / or functional changes Pulmozim or other component of the mixture.
2.5 mg dornase alpha (corresponds to the content of 1 mg – 2.5 ml of the undiluted solution, 2500 U) once per day by inhalation, without dilution, using a jet nebulizer (see. “on the treatment of drug Instructions” section).
in some patients over 21 years of the best treatment effect can be achieved by applying a daily dose 2 times a day. In most patients, the optimal effect can be achieved with constant daily use Pulmozim.Studies in which dornase alfa administered intermittently, show that after cessation of therapy, improvement of pulmonary function disappears. Therefore, patients should be recommended daily intake of the drug without interruption.
Patients should continue to complex therapy, including chest physiotherapy.
In acute respiratory tract infections during treatment Pulmozim its use can be continued primobolan depot for sale without any risk for the patient.
How to handle drug
contents of one ampoule must be poured into the tank jet nebuliser / compressor type Hudson T Up-draft II / Pulmo -Aide, Airlife Misty / Pulmo-Aide, modification Respigard / Pulmo-Aide or Acorn II / Pulmo-Aide .
Pulmozyme can be administered jet nebuliser / compressor reusable type Pari LL / Inhalierboy, Pari LC / Inhalierboy or Master, Aiolos / 2 Aiolos, Side Stream / CR50, Mobil Air or Porta-Neb.
Patients unable to breathe through the mouth during the entire period inhalation via nebulizer may use a nebulizer Pari Baby with a tight-fitting face mask.
Ultrasonic nebulizers are not suitable for administration Pulmozim because they may inactivate Pulmozyme or have unacceptable aerosol characteristics.
The patient must comply with company-manufacturer’s instructions for use and care of the nebulizer / compressor .
Adverse reactions in the treatment Pulmozim are rare (<1/1000), in most cases are mild, are transient in nature and do not require dose adjustment. From the side of hematopoiesis: acute lymphocytic leukemia, aplastic anemia. From the nervous system: seizures, migraine. From the senses: conjunctivitis, disequilibrium. On the part of the cardiovascular system: tachycardia, bradycardia, cardiac arrest.On the part of the respiratory system: pneumonia, bronchitis, respiratory tract infection, including due of Pseudomonas, pharyngitis, laryngitis, voice alteration (hoarseness), dyspnoea, rhinitis, worsening of pulmonary function, reduced respiratory function, respiratory failure, hemoptysis, pneumothorax, pulmonary hemorrhage, polyp throat, cough, increased bronchial secretions, alveolitis, hypoxia, bronchospasm, productive cough. On the part of the gastrointestinal tract: dyspepsia, abdominal pain, bloody vomiting, liver failure. With the skin side and its appendages: rash, itching, hives, dermatitis, purpura, angioedema. pregnancy, postpartum: premature birth, complications during pregnancy, miscarriage, medical abortion. On the part of the body as a whole: . pleural chest pain, fever, fatigue, malaise, death Patients who develop adverse events that coincide with the symptoms of cystic fibrosis can usually continue using Pulmozim. Adverse events leading to the complete cessation of treatment Pulmozim, observed in a very small number of patients, and the frequency of interruption of therapy was similar with placebo appointment (2%) and dornase alfa (3%). The antibodies to dornase alfa were found in less than 5% of patients, but none of them are not classified as IgE. Improved lung function was noted even after the appearance of antibodies to dornase alfa.